146 related articles for article (PubMed ID: 12696062)
1. Peculiar structure and location of 9p21 homozygous deletion breakpoints in human cancer cells.
Florl AR; Schulz WA
Genes Chromosomes Cancer; 2003 Jun; 37(2):141-8. PubMed ID: 12696062
[TBL] [Abstract][Full Text] [Related]
2. Homozygous deletions of CDKN2A caused by alternative mechanisms in various human cancer cell lines.
Raschke S; Balz V; Efferth T; Schulz WA; Florl AR
Genes Chromosomes Cancer; 2005 Jan; 42(1):58-67. PubMed ID: 15495191
[TBL] [Abstract][Full Text] [Related]
3. Molecular processes of chromosome 9p21 deletions in human cancers.
Sasaki S; Kitagawa Y; Sekido Y; Minna JD; Kuwano H; Yokota J; Kohno T
Oncogene; 2003 Jun; 22(24):3792-8. PubMed ID: 12802286
[TBL] [Abstract][Full Text] [Related]
4. Molecular processes of chromosome 9p21 deletions causing inactivation of the p16 tumor suppressor gene in human cancer: deduction from structural analysis of breakpoints for deletions.
Kohno T; Yokota J
DNA Repair (Amst); 2006 Sep; 5(9-10):1273-81. PubMed ID: 16931177
[TBL] [Abstract][Full Text] [Related]
5. Two regions of homozygous deletion clusters at chromosome band 9p21 in human lung cancer.
Hamada K; Kohno T; Takahashi M; Yamazaki M; Yamazaki M; Tashiro H; Sugawara C; Ohwada S; Sekido Y; Minna JD; Yokota J
Genes Chromosomes Cancer; 2000 Mar; 27(3):308-18. PubMed ID: 10679921
[TBL] [Abstract][Full Text] [Related]
6. Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR.
Berggren P; Kumar R; Sakano S; Hemminki L; Wada T; Steineck G; Adolfsson J; Larsson P; Norming U; Wijkström H; Hemminki K
Clin Cancer Res; 2003 Jan; 9(1):235-42. PubMed ID: 12538475
[TBL] [Abstract][Full Text] [Related]
7. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
[TBL] [Abstract][Full Text] [Related]
8. Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas.
Cairns P; Tokino K; Eby Y; Sidransky D
Cancer Res; 1995 Jan; 55(2):224-7. PubMed ID: 7812948
[TBL] [Abstract][Full Text] [Related]
9. Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer.
Stadler WM; Sherman J; Bohlander SK; Roulston D; Dreyling M; Rukstalis D; Olopade OI
Cancer Res; 1994 Apr; 54(8):2060-3. PubMed ID: 7513608
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of homozygous deletions and multiple duplications at the CDKN2A (p16INK4a)/ARF (p14ARF) locus in urinary bladder cancer.
Berggren de Verdier PJ; Kumar R; Adolfsson J; Larsson P; Norming U; Onelöv E; Wijkström H; Steineck G; Hemminki K
Scand J Urol Nephrol; 2006; 40(5):363-9. PubMed ID: 17060081
[TBL] [Abstract][Full Text] [Related]
11. Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer.
Tsutsumi M; Tsai YC; Gonzalgo ML; Nichols PW; Jones PA
Oncogene; 1998 Dec; 17(23):3021-7. PubMed ID: 9881704
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of a homozygous deletion found in ovarian ascites by representational difference analysis.
Watson JE; Gabra H; Taylor KJ; Rabiasz GJ; Morrison H; Perry P; Smyth JF; Porteous DJ
Genome Res; 1999 Mar; 9(3):226-33. PubMed ID: 10077528
[TBL] [Abstract][Full Text] [Related]
13. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.
Knappskog S; Geisler J; Arnesen T; Lillehaug JR; Lønning PE
Genes Chromosomes Cancer; 2006 Dec; 45(12):1155-63. PubMed ID: 17001621
[TBL] [Abstract][Full Text] [Related]
14. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization.
Balázs M; Carroll P; Kerschmann R; Sauter G; Waldman FM
Genes Chromosomes Cancer; 1997 Jun; 19(2):84-9. PubMed ID: 9171998
[TBL] [Abstract][Full Text] [Related]
15. The presence of multiple regions of homozygous deletion at the CSMD1 locus in oral squamous cell carcinoma question the role of CSMD1 in head and neck carcinogenesis.
Toomes C; Jackson A; Maguire K; Wood J; Gollin S; Ishwad C; Paterson I; Prime S; Parkinson K; Bell S; Woods G; Markham A; Oliver R; Woodward R; Sloan P; Dixon M; Read A; Thakker N
Genes Chromosomes Cancer; 2003 Jun; 37(2):132-40. PubMed ID: 12696061
[TBL] [Abstract][Full Text] [Related]
16. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia.
Bertin R; Acquaviva C; Mirebeau D; Guidal-Giroux C; Vilmer E; Cavé H
Genes Chromosomes Cancer; 2003 May; 37(1):44-57. PubMed ID: 12661005
[TBL] [Abstract][Full Text] [Related]
17. Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas.
Weber RG; Hoischen A; Ehrler M; Zipper P; Kaulich K; Blaschke B; Becker AJ; Weber-Mangal S; Jauch A; Radlwimmer B; Schramm J; Wiestler OD; Lichter P; Reifenberger G
Oncogene; 2007 Feb; 26(7):1088-97. PubMed ID: 16909113
[TBL] [Abstract][Full Text] [Related]
18. Homozygous deletions within the 11q13 cervical cancer tumor-suppressor locus in radiation-induced, neoplastically transformed human hybrid cells.
Mendonca MS; Farrington DL; Mayhugh BM; Qin Y; Temples T; Comerford K; Chakrabarti R; Zainabadi K; Redpath JL; Stanbridge EJ; Srivatsan ES
Genes Chromosomes Cancer; 2004 Apr; 39(4):277-87. PubMed ID: 14978789
[TBL] [Abstract][Full Text] [Related]
19. Identification of chromosome arm 9p as the most frequent target of homozygous deletions in lung cancer.
Sato M; Takahashi K; Nagayama K; Arai Y; Ito N; Okada M; Minna JD; Yokota J; Kohno T
Genes Chromosomes Cancer; 2005 Dec; 44(4):405-14. PubMed ID: 16114034
[TBL] [Abstract][Full Text] [Related]
20. Homozygous deletion mapping at 9p21 in bladder carcinoma defines a critical region within 2cM of IFNA.
Devlin J; Keen AJ; Knowles MA
Oncogene; 1994 Sep; 9(9):2757-60. PubMed ID: 8058343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
